NewAmsterdam wins CHMP backing for obicetrapib ahead of PREVAIL
NewAmsterdam Pharma has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending marketing authorisation for obicetrapib 10 mg as a monotherapy and as a fixed-dose combination (FDC) with ezetimibe 10 mg. The CHMP opinion, adopted in July 2026, covers patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and mixed dyslipidaemia. A final European Commission decision is expected before year-end. If granted, European commercialisation rights sit with Menarini Group under an existing licence agreement.
The Netherlands-headquartered, Nasdaq-listed company also reported second-quarter financials, closing 30 June 2026 with $678.3 million in cash, cash equivalents and marketable securities. Net loss for the quarter was $64.1 million, up from $17.4 million in the same period last year, reflecting higher R&D spend as multiple Phase 3 programmes advanced simultaneously. R&D expenses rose to $41.7 million from $27.5 million year-on-year, while SG&A held broadly flat at $26.9 million.
Clinical pipeline and upcoming milestones
The most consequential near-term catalyst is PREVAIL, NewAmsterdam's cardiovascular outcomes trial enrolling more than 9,500 patients with established atherosclerotic cardiovascular disease whose LDL-C remains inadequately controlled on maximally tolerated lipid-lowering therapy. An interim analysis is planned for the fourth quarter of 2026, with results expected in the first quarter of 2027. A positive interim signal would substantially de-risk the commercial thesis and could prompt accelerated regulatory dialogue in the United States, where obicetrapib does not yet have an approved indication.
Separately, the smaller RUBENS Phase 3 trial, initiated in December 2025 and evaluating obicetrapib in patients with type 2 diabetes or metabolic syndrome, is expected to deliver topline data by year-end 2026. The REMBRANDT imaging sub-study, which uses coronary CT angiography to assess plaque burden with the obicetrapib/ezetimibe FDC, completed enrolment of 323 patients in March 2026.
NewAmsterdam also presented data at the Alzheimer's Association International Conference in July 2026, reporting statistically significant reductions in plasma p-tau217, a key biomarker of Alzheimer's disease pathology, versus placebo in a pre-specified analysis from the BROADWAY trial (p=0.002, n=1,535). The company said it intends to initiate a dedicated early Alzheimer's disease prevention trial before the end of 2026, broadening the potential addressable market well beyond the cardiovascular indication.
Market context and competitive positioning
Obicetrapib is a CETP inhibitor, a class with a troubled history: earlier high-dose CETP inhibitors from other developers failed cardiovascular outcomes trials, in some cases showing harm. NewAmsterdam's differentiation rests on a low-dose, once-daily oral profile and a safety signal it says is comparable to placebo across multiple Phase 3 studies. The company argues that LDL-C and lipoprotein(a) lowering jointly mediated 84.5% of the observed MACE reduction in a pooled mediation analysis of BROADWAY and BROOKLYN.
The broader LDL-lowering market remains competitive. PCSK9 inhibitors from Amgen and Sanofi/Regeneron hold established positions in high-risk patients, and inclisiran, Novartis's small-interfering RNA therapy, offers a twice-yearly injectable option. An oral, once-daily non-statin that also signals potential benefit in Alzheimer's disease prevention would occupy a distinct niche, but the PREVAIL outcome is the central test of whether the cardiovascular benefit is real and durable at scale. Investors attending NewAmsterdam's Investor Day on 5 August will be watching management's framing of the PREVAIL interim timeline above all else.